CACLP - The largest IVD Expo & Conference

Lucira Health Posts $12.4M in Revenues, Beats Wall Street Estimate

Industry news | 13 August, 2021 | CACLP

Original from Genomeweb


Lucira Health reported on Thursday after the close of the market that it had $12.4 million in revenues for the second quarter, the firm's second full quarter of commercial activity.


The Emeryville, California-based developer of molecular diagnostics for infectious diseases went public in February. For the quarter ended June 30, Lucira recorded sequential growth of 175 percent, from $4.5 million in Q1, and beat the consensus Wall Street estimate of $8 million. It did not have any revenues in the year-ago quarter.


"We are continuing to generate strong growth across all areas of the business," Lucira CEO Erik Engelson said in a statement.


Lucira manufactures an over-the-counter COVID-19 PCR test kits called Check It, which has Emergency Use Authorization from the US Food and Drug Administration, as well as an EUA prescription-use test kit called All-In-One. To meet negative test verification requirements, Check It provides an SMS-verified digital test result called Luci Pass back to a user's phone.


The company noted that it partnered with Meenta to customize a workflow for the Lucira All-In-One test kit that was utilized by athletes and individuals traveling to Japan this summer. The firm also partnered with Azova, which negotiated to authorize pairing the Lucira Check It test kit with Azova's video observation services to meet requirements for travel to Hawaii.


"We have also invested in establishing an infrastructure to support the accelerating demand for our test kits," Engelson noted. "We look forward to continuing to establish ourselves as market leaders in the at-home testing space in the second half of 2021 and beyond."


The company posted a Q2 net loss of $16.2 million, or $.42 per share, compared to a net loss of $6.6 million, or $2.90 per share, a year ago. It missed the consensus Wall Street estimate for a net loss of $.32 per share.


The weighted average number of shares used to calculate the loss per share in Q2 was about 38.5 million compared to fewer than 2.3 million in Q1 2020.


Lucira's Q2 R&D spending more than doubled year over year to $10.1 million from $4.6 million. SG&A costs increased more than sixfold to $6.1 million from $931,000 a year ago.


The firm exited Q2 with $161.7 million in cash.



Source: Lucira Health Posts $12.4M in Revenues, Beats Wall Street Estimate | Genomeweb

Filed under:
Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference